Corpus Uteri | Larynx | Lung | Soft Tissue | Unknown Sites, Phase II
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
This is a multi-cohort, open-label, Phase 2 study designed to assess the clinical activity of sacituzumab govitecan in adult subjects with metastatic solid tumors with elevated Trop-2 expression.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Aarti Bhatia, MD, MPH
- Anne Chiang, MD, PhD
- Barbara Burtness, MD
- Blair Colette McNamara, MD
- Elena Ratner, MD, MBA
- Emily Duffield, APRN
- Frederick Wilson, MD, PhD
- Gary Altwerger, MD
- Hari Deshpande, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Justin Harold, MD
- Kathryn Medow, APRN
- Lynsey Teulings
- Marianne Davies, NP, DNP, MSN, BSN
- Masoud Azodi, MD
- Michael Cecchini, MD
- Nesrine Khoury
- Peter Schwartz, MD
- Rebecca Bartomeli
- Roy S. Herbst, MD, PhD
- Sarah Goldberg, MD, MPH
- Scott Gettinger, MD
- Stacey Stein, MD
- Stephanie Cerrito
- Vaagn Andikyan, MD
- Last Updated03/10/2023
- Study HIC#2000025243